Compare KFFB & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KFFB | FEMY |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 37.2M |
| IPO Year | 2004 | 2021 |
| Metric | KFFB | FEMY |
|---|---|---|
| Price | $4.54 | $0.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.83 |
| AVG Volume (30 Days) | 2.5K | ★ 480.3K |
| Earning Date | 05-21-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 109.52 | 8.60 |
| EPS | ★ 0.08 | N/A |
| Revenue | $15,000.00 | ★ $1,629,108.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | N/A | $147.19 |
| P/E Ratio | $60.27 | ★ N/A |
| Revenue Growth | N/A | ★ 51.97 |
| 52 Week Low | $1.96 | $0.31 |
| 52 Week High | $4.98 | $1.76 |
| Indicator | KFFB | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.14 |
| Support Level | N/A | $0.33 |
| Resistance Level | N/A | $0.57 |
| Average True Range (ATR) | 0.00 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 82.30 |
Kentucky First Federal Bancorp is a holding company. The company, through its subsidiaries, is engaged mainly in the business of accepting deposits from the general public and using such funds to originate loans secured by first mortgages on owner-occupied, residential real estate and other loans secured by real estate. Its primary products and services include Residential mortgage loans, Multi-family loans, Construction loans, and types of deposits etc. The company mainly operates in Perry, Franklin, Boyle, and Garrard and surrounding counties in Kentucky, USA.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.